UroGen Pharma (URGN) PT Lowered to $52 at Oppenheimer
Tweet Send to a Friend
Oppenheimer analyst Leland Gershell lowered the price target on UroGen Pharma (NASDAQ: URGN) to $52.00 (from $62.00) while maintaining an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
